| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Human prion disease (HPD) is 100% lethal rapidly progressive dementia, and no diagnostic or therapeutic method for HPD has yet been established. We have succeeded for the first time in the world in detecting the abnormal prion proteins in the CSF of patients with HPD. The purpose of this study is to attempt an innovative and non-invasive diagnosis of HPD from non-CNS organs containing blood ahead of the rest of the world. From 2017 to March 2021 , based on the research results so far, an epoch-making diagnostic method was established based on four studies. （1） Establish semi-quantification of trace amounts of abnormal prion protein, especially in human samples. (2)Analysis of stored samples and 4-year retrospective study will be conducted to establish sensitivity and specificity for diagnosis from CSF, and semi-quantification will also be performed. (3) We developed a new detection method for abnormal prion proteins from samples of HPD patients, and examined its effectiveness.
|
